

# Index

- Abortion, grief reaction to, 362–363
- Abuse, physical/sexual  
depression risk, 151  
epidemiology, 543, 544  
implications for mental health care, 621  
outcomes, 545–546, 547  
pregnancy outcomes, 548  
premenstrual symptoms related to, 54  
reporting behaviors, 543–544  
risk factors, 543  
schizophrenia outcomes, 186–187  
subsequent personality disorder risk, 329, 330–331  
subsequent substance abuse and, 227  
*see also* Trauma exposure
- Acromegaly, 413
- Acupuncture, 349–350
- Addison's disease, 413–414
- Adolescents  
anxiety disorders among, 196  
body dysmorphic disorder among, 298  
gender socialization process, 507  
lesbian, 557–558  
pregnancy prevention, 120–121
- Adrenocorticotrophic hormone, 3, 4, 7, 9, 404
- Adrenogenital syndrome, 415–416
- Agoraphobia, 195, 201, 206
- AIDS/HIV, 231  
biopsychosocial interventions, 459–463  
course, 454–455  
delirium and dementia in, 458, 461  
epidemiology, 452–454  
gynecological conditions in, 455  
mortality, 454  
mother-to-child transmission, 455  
psychiatric complications, 457–459  
psychiatric consultation in, 452, 456–457, 462–463  
substance use disorders and, 458–459  
trauma exposure and, 547
- Alcohol use and abuse  
among older women, 226, 588  
associated factors, 227–229  
biological response, 229–231  
depression and, 232–233  
drinking patterns, 224–226  
effects on sleep, 281–282  
epidemiology, 222–224  
mortality, 230  
panic disorder and, 202  
during pregnancy, 231–232  
psychiatric comorbidity, 232–233  
schizophrenia and, 187  
social factors, 224  
violence exposure risk in, 543  
*see also* Substance abuse
- Aldosterone, 412
- Alzheimer's disease  
clinical features, 476  
epidemiology, 475, 586  
etiology, 475–476  
management, 476–477, 587  
pathogenesis, 475
- Amphetamines, 282
- Anorexia nervosa  
clinical conceptualization, 244  
comorbidity, 250–251  
course, 246  
diagnosis, 245, 249–250  
epidemiology, 247, 248  
infertility in, 253  
management, 252, 253, 254–255  
menstrual irregularities in, 253  
outcomes, 257  
physiological complications, 251  
pregnancy and, 253–254  
*see also* Eating disorders
- Antibiotic drug interactions, 126–127
- Anticonvulsant drugs  
drug interactions, 126  
fetal exposure, 78–79, 170–171
- Antidepressant medications  
AIDS/HIV and, 460  
in Alzheimer's disease management, 477  
breastfeeding and, 102–103  
drug interactions, 138–139, 446–447  
effects on sexual functioning, 267–268, 269–270  
fibromyalgia treatment, 395  
insomnia treatment, 284  
for multiple sclerosis, 475  
for pain disorder with psychological features, 319–320  
sex differences in pharmacokinetics, 39–40, 41  
sex differences in pharmacotherapy, 155–157  
thyroid hormone augmentation, 412  
use during pregnancy, 73–75, 80–81
- Antipsychotic medications  
AIDS/HIV and, 461  
in Alzheimer's disease management, 477  
diabetes mellitus risk, 408  
fetal exposure, 76–77, 171  
prolactin regulation by, 416  
schizophrenia pharmacokinetics, 188–189  
sex differences in pharmacokinetics, 37–38, 41  
side effects, 38
- Antisocial personality disorder, 323, 325, 326, 329–331, 332
- Anxiety/anxiety disorders  
age at onset, 195  
AIDS/HIV and, 461  
alcohol use and, 232  
among elderly, 589  
assessment and diagnosis, 196  
body dysmorphic disorder and, 297, 298  
cancer response, 382  
cardiac disease and, 430  
comorbidity, 196, 332–333  
cosmetic surgery and, 488

- Anxiety/anxiety disorders  
(*continued*)  
depression and, 150  
epidemiology, 195  
hormonal contraception and,  
123–124  
hypothalamic–pituitary–adrenal  
axis in, 7–8  
lactation effects, 14  
menstrual cycle influences, 12–13  
outcomes, 196  
during pregnancy, 82–83  
pregnancy effects, 13–14  
premenstrual disorder and, 50,  
53  
reproductive cycle correlations,  
197  
risk factors, 196–197  
sex differences, 4, 6, 12, 195–  
198  
sleep abnormalities in, 288  
stress and, 3–4, 18  
*see also* Panic disorder; specific  
diagnosis
- Anxiolytic drugs, 59
- Aspirin, 424
- Assisted reproductive technology,  
359–360
- Athletes, eating disorders among,  
247
- Avoidant personality disorder, 206,  
324
- B**
- Bad breath, 438
- Benzodiazepines  
abuse and dependence, 231, 233  
among elderly, 588–589  
AIDS/HIV and, 461  
drug interactions, 127  
effects on sleep patterns, 284,  
287  
fetal exposure, 75–76  
panic disorder management,  
204  
personality disorder treatment,  
335  
sex differences in  
pharmacokinetics, 38–39  
social anxiety disorder treatment,  
207
- Bereavement and grieving  
in abortion, 362–363  
in fetal death, 361–362  
in infertility, 359–360  
in pregnancy loss, 361  
in reproductive events, 359
- Binge eating disorder, 246–247,  
248–249
- Biofeedback, 351
- Bipolar disorder, 81–82  
age at onset, 134  
in AIDS/HIV, 457  
breastfeeding during  
pharmacotherapy, 172–174  
case history, 174–175  
clinical features, 166, 615–616  
comorbidity, 167  
course, 166–167, 616  
diabetes mellitus and, 407–408  
differential diagnosis, 175  
epidemiology, 166, 615  
evaluation, 175  
genetic risk, 169  
menopause and, 175  
menstrual cycle and, 168–169  
in postpartum period, 172  
pregnant patient, 169–172  
sex differences, 166–176  
sleep abnormalities in, 288  
treatment, 167–168
- Birth control. *see* Contraception,  
hormonal
- Body dysmorphic disorder  
associated demographic  
characteristics, 296  
behavioral manifestations, 297  
cognitive functioning in, 297  
comorbidity, 298  
complications, 297–298  
cosmetic surgery and, 486–487,  
491–492  
course, 298–299  
diagnosis, 295, 299–300  
effects on reproductive life, 299  
epidemiology, 295–296, 311  
focus of preoccupation, 296–297  
outcomes, 298–299  
during pregnancy, 303  
research needs, 304  
treatment, 300–304
- Borderline personality disorder,  
323, 325, 328–329, 331–332,  
334–336
- Breast cancer  
advanced disease, 374  
alcohol use and, 230  
bone marrow transplantation for,  
374  
chemotherapy, 373  
early detection and prevention,  
370–371  
epidemiology, 369  
estrogen use and, 427  
family functioning, 375  
hormonal contraception and,  
116  
hormonal therapy, 374  
lumpectomy, 373  
mastectomy, 371, 372–373  
medical decision-making, 370,  
371, 373  
metastatic disease, 374  
prevention, 374  
prognosis, 369–370  
psychological aspects, 371–372  
psychosocial interventions, 374  
radiation therapy, 373
- Breastfeeding and lactation, 14  
pharmacotherapy and, 102–103,  
172–174
- Bulimia nervosa  
body dysmorphic disorder and,  
298  
comorbidity, 251  
course, 246  
diagnosis, 245, 249–250  
epidemiology, 247, 248  
management, 252–253, 255–  
256  
outcomes, 257  
physiological complications,  
251  
pregnancy and, 253–254  
*see also* Eating disorders
- C**
- Caffeine, 282
- Calcium, premenstrual symptoms  
and, 56
- Cancer  
future research directions, 384  
gynecological, 376–377, 380  
medical decision making, 384  
psychological response, 376, 377  
screening and prevention, 384  
sexual functioning and, 377  
stigmatization response, 376  
treatment-related changes, 377  
*see also* specific site; specific type
- Candidiasis in HIV/AIDS, 455
- Cardiovascular disease  
arrhythmias, 251  
cardiac rehabilitation programs,  
426  
cardiac transplantation, 425  
congestive heart failure, 425  
coronary artery bypass grafting,  
424–425  
drug-related, 606  
eating disorder complications,  
251  
gender differences, 422–427  
hormonal contraception side  
effects, 116  
mortality, 422, 424  
presentation, 423  
psychiatric consultation in, 430–  
431  
reproductive hormones and,  
426–427  
research on women's health,  
422–423, 431–432  
risk factors, 423, 428–430  
sexual functioning and, 426
- Catecholamines, 414
- Cervical cancer  
AIDS/HIV and, 455  
prevention, 378  
prognosis, 378  
risk, 378  
symptoms, 378  
treatment-related problems, 378
- Chemotherapy, 373
- Choking, fear of, 438–439
- Chronic fatigue syndrome  
clinical features, 390–391  
diagnosis, 391–392  
epidemiology, 391  
prognosis, 392  
treatment, 392–393
- Chronic pelvic pain, 363–366
- Circadian rhythms, 135–136  
light exposure therapy, 286  
pharmaceutical research, 605  
sleep architecture, 278–279
- Cognitive functioning  
AIDS/HIV complications, 458,  
461  
in Alzheimer's disease, 476  
in body dysmorphic disorder,  
296–297  
dementia, 458, 461, 586  
gender differences in coping, 621  
gender socialization, 508–509  
multiple sclerosis complications,  
473  
in schizophrenia, 185–186

- Colostomy, 443–444
- Complementary and alternative medicine
- acupuncture, 349–350
  - chiropractic medicine, 350
  - definition, 345
  - future prospects, 352
  - herbal medicine, 346–348
  - historical development, 345–346
  - homeopathy, 348–349
  - mind–body medicine, 350–351
  - practices, 345, 346
  - utilization, 344, 346
  - yoga, 351–352
- Congestive heart failure, 425
- Contraception, hormonal
- adolescent use, 120–121
  - among women with eating disorders, 122
  - cardiac disease and, 426–427
  - contraindications, 117–118
  - drug interactions, 125–127
  - effects on metabolism, 125
  - effects on sexual functioning, 124–125
  - efficacy, 115, 126
  - emergency formulations, 120
  - future prospects, 133
  - gastrointestinal complications, 439
  - health benefits, 116–117
  - menstrual migraine and, 470
  - neuropsychiatric considerations, 122–125
  - oral contraceptive pills, 114, 115–117, 122–123
  - progestin-only, 118–120
  - selection, 115
  - sexual behavior and, 263
  - side effects, 115–116
  - utilization, 114
- Conversion disorder
- comorbidity, 313
  - diagnostic criteria, 307
  - epidemiology, 311
  - presentation, 311
  - treatment response, 318–319
- Coping style, 150
- Coronary artery bypass grafting, 424–425, 426
- Corticotropin-releasing hormone, 3, 4, 5, 7–8
- Cosmetic surgery
- anxiety disorders and, 488
  - body dysmorphic disorder and, 486–487, 491, 492
  - body image satisfaction, 484–486, 491–492
  - common procedures, 481
  - eating disorders and, 488
  - liposuction, 488
  - patient expectations, 490–491
  - personality disorders and, 488–489
  - psychiatric consultation, 490–492
  - psychological outcomes, 482–484, 486–489, 492
  - psychotic disorders and, 487–488
  - utilization, 481
- Crohn's disease, 442–443, 444
- Cushing's syndrome, 413
- Cytochrome P450 enzyme
- in drug interactions, 125–126
  - ethnic differences in, 579
  - isoenzymes, 33–34
  - pharmacokinetic action, 32–33, 35–36
  - sex differences, 35
- D**
- Day care, 530–531
- Dementia
- in AIDS, 458, 461
  - epidemiology, 586
  - see also Alzheimer's disease
- Dependent personality disorder, 324
- Depo Provera, 118–119, 121
- Depot medroxyprogesterone acetate, 118–119, 121
- Depression
- age at onset, 133–134, 148, 149
  - in AIDS/HIV, 457, 460
  - among elderly, 585–586
  - among perimenopausal women, 121–122
  - anxiety linkage, 150
  - body dysmorphic disorder and, 298
  - cardiac disease and, 429–430
  - comorbidity, 153–154, 201, 333–334
  - course, 154, 615
  - diabetes mellitus and, 407, 408
  - divorce and, 521
  - employment status and, 151–152
  - epidemiology, 147–148, 615
  - estrogen and, 135–136
  - estrogen replacement therapy, 137–139, 586
  - genetic transmission, 149–150
  - gynecological cancer and, 376
  - hormonal contraception and, 121–122, 123–124
  - hormonal system in, 148–149
  - hypothalamic–pituitary–adrenal axis in, 7–8, 412–413
  - marital status and, 151
  - maternal, 95–96
  - menopause and, 133–137, 137
  - menstruation cycle and, 154–155
  - in multiple sclerosis, 473
  - outcomes, 615
  - postpartum, 93–94, 103, 149, 620, 624
  - precipitating factors, 154–155
  - during pregnancy
  - fetal development and, 72–73
  - treatment, 80–81
  - premenstrual disorder and, 50, 52, 149
  - research needs, 158–159
  - in rheumatoid arthritis, 398
  - risk, 147, 148–152
  - severity, 152
  - sex differences, 4, 6, 147–155, 621
  - sleep abnormalities in, 287–288
  - socialization processes and, 150
  - somatiform disorder
  - comorbidity, 313
  - stress and, 3–4, 18, 150–151, 154
  - substance abuse and, 227–228, 232, 233
  - suicide risk, 152–153
  - symptoms, 152
  - thyroid function in, 410, 412
  - trauma experiences and, 151
  - treatment, 155–158
- Depressive personality disorder, 324, 329
- Developmental processes
- abuse outcomes, 546
  - cultural identity in, 572–574
  - effects of maternal mental illness, 95–96
  - gender-based toy preferences, 501
  - gender constancy, 500
  - gender differences among elderly, 584
  - gender identity formation, 499–500
  - gender role identity, 499, 501–502, 523
  - gender scripts and schemas, 502–503, 507
  - gender stereotypes, 500, 501, 502–503
  - lesbian life cycle, 557–559
  - see also Gender socialization
- Dexamethasone metabolism in pregnancy, 13
- Diabetes mellitus
- classification, 405
  - implications for family functioning, 406
  - management, 405, 409–410
  - medical complications, 406
  - psychopathology risk, 407–410
  - psychosocial problems in, 405–406
  - sexual dysfunction in, 406–407
- Diet and nutrition
- migraine precipitants, 468–469
  - premenstrual symptom management, 56–58
- Discrimination
- immigrant experience, 575
  - against lesbian women, 556
  - outcomes, 534–535
  - in workplace, 529, 533
- Dissociation, as trauma response, 547
- Divorce
- cultural context, 521
  - depression reactions, 521
  - financial outcomes, 522
  - initiation of, 522
  - long-term outcomes, 523
  - parenting and, 522–523
  - stress reactions, 521
  - trends, 521
- Domestic abuse/violence
- epidemiology, 543
  - outcomes, 545–546, 547
  - screening, 620
- Drug interactions
- in AIDS/HIV
  - psychopharmacology, 460
  - in bipolar disorder treatment, 168
  - cytochrome P 450 in, 125–126
  - estrogen replacement therapy, 138–139

- Drug interactions (*continued*)  
 hormonal contraceptives, 125, 126–127  
 liver metabolism and, 446–447  
 Dismorphophobia. *see* Body dysmorphic disorder
- E**
- Eating disorders  
 age at onset, 248–249  
 assessment and diagnosis, 244, 249–250  
 binge eating disorder, 246–247, 248–249  
 classification, 244  
 comorbidity, 250–251  
 cosmetic surgery and, 488  
 diabetes mellitus and, 408–409  
 epidemiology, 247–249  
 etiology, 244  
 female athlete triad, 247  
 future research directions, 257–258  
 hormonal contraceptive use and, 122  
 laboratory evaluation, 251–252  
 management, 252–253  
 menstrual irregularities in, 253  
 night-eating syndrome, 247, 248  
 not otherwise specified, 245–247  
 substance abuse and, 229  
*see also* Anorexia nervosa; Bulimia nervosa
- Ectopic pregnancy, 117
- Education, gender socialization in, 504
- Elder care, 537
- Electroconvulsive therapy, 158
- Emergency contraception, 120
- Employment  
 current profile, 528  
 discrimination in, 529, 533  
 dual-career couples, 530–531  
 dual-paycheck couples, 531  
 elder care and, 537  
 family role and, 528, 529–530  
 gender equity in, 528  
 marriage patterns, 530  
 mental health benefits of working, 530  
 microinequities, 534  
 role conflict/strain for working women, 531–532, 536–537, 538  
 sexual harassment in, 533, 534–536  
 sociocultural evolution, 528–529, 538  
 stressors in, 529  
 stress reduction strategies, 532–533, 538–539  
 tokenism in, 533–534  
 women's status in, 527–528  
 work inhibitions, 536
- Endocrine system  
 assessment, 417  
 diabetes mellitus, 407–410  
 hormonal contraceptive effects, 125  
 hypothalamic–pituitary–adrenal axis disorders, 412–416  
 hypothalamic–pituitary–thyroid axis, 410–412  
 pituitary function/dysfunction, 404–405  
 psychiatric manifestations, 404  
 Endometrial cancer, 117, 378–379, 427
- Estrogen  
 Alzheimer's disease and, 476, 477, 587  
 anxiety and, 12–13, 18, 197  
 cancer risk, 427  
 effects on metabolism, 125  
 effects on sleep, 276–277  
 gamma-aminobutyric acid interaction, 17  
 glutamate systems interaction, 16–17  
 in menopausal depression, 135–136  
 migraine and, 469–470, 471  
 neurochemical action, 135  
 in oral contraceptive pill, 114  
 in panic disorder  
 pathophysiology, 203  
 receptor activity, 6  
 in serotonergic regulation, 15, 125  
 in stress response, 9, 10
- Estrogen replacement therapy  
 Alzheimer's disease management, 477  
 bipolar disorder treatment, 168  
 cancer risk, 379  
 cardiac disease and, 426–427  
 depression and, 586  
 menopausal depression and, 137–139  
 for premenstrual disorders, 61  
 sleep changes in, 138  
 treatment of postpartum mental disorders, 101  
 utilization factors, 427
- Ethical treatment, 622–624
- Ethinyl estradiol  
 effects on metabolism, 125  
 in morning-after pills, 120  
 in oral contraceptive pill, 114, 122  
 perimenopausal use, 122
- Exercise, 423
- F**
- Family functioning  
 breast cancer management, 375  
 diabetes mellitus-related disruptions, 406  
 elder care stress, 537  
 gender socialization and, 504, 505–506  
 lesbian coming-out, 560–561  
 role conflict/strain for working women, 528, 529–530, 531–532, 536–537  
 single-parent households, 520–521  
*see also* Parenting
- Fatigue, 312
- Female athlete triad, 247
- Fetal development  
 anticonvulsant drug exposure, 78–79  
 antidepressant drug exposure, 73–75, 80–81  
 antipsychotic drug exposure, 76–77  
 benzodiazepine exposure effects, 75–76  
 bipolar disorder  
 pharmacotherapy risk, 169–172  
 HIV transmission, 455  
 lithium exposure, 77–78  
 malformation risk, 71–72  
 maternal depression and, 72–73  
 maternal psychopharmacotherapy and, 70–72  
 maternal sleep patterns and, 278  
 maternal substance use, 231–232  
 stress effects, 11
- Fibromyalgia  
 clinical features, 393  
 diagnosis, 393, 394  
 epidemiology, 393  
 etiology, 393–394  
 prognosis, 394–395  
 treatment, 395
- Follicle-stimulating hormone, 404, 405
- Food and Drug Administration, 597–598, 599
- G**
- Gamma-aminobutyric acid, 7, 14, 17, 203
- Gastroesophageal reflux disease, 439–440
- Gastrointestinal disorders  
 assessment, 437, 447  
 disorders of taste and swallowing, 438–439  
 gastroesophageal reflux disease, 439–440  
 inflammatory bowel disease, 442–444  
 irritable bowel syndrome, 444–446  
 nausea during pregnancy, 441–442  
 obesity, 440–441  
 peptic ulcer disease, 442  
 as somatization, 437–438
- Gender socialization  
 biological–environmental interaction model, 510–512  
 challenges for working women, 536–537  
 clinical significance, 499  
 cognitive-developmental model, 506–507  
 conceptual framework, 503–505  
 cultural context, 504–505  
 depression and, 150  
 developmental constructs, 499–503  
 evolutionary theory, 508–509  
 feminist thought, 507–508  
 gender polarization model, 507–508  
 marriage and, 517–518  
 neuropsychological theories, 509–510  
 psychoanalytic theory, 505

- social learning model, 505–506, 523  
 stresses for women, 523
- Generalized anxiety disorder  
 clinical features, 198  
 comorbidity, 198–199  
 epidemiology, 195, 198  
 gender differences, 198–200  
 neurophysiology, 199–200  
 outcomes, 199  
 reproductive cycle correlations, 200  
 risk factors, 199  
 treatment, 200
- Glossodynia, 438
- Glucocorticoid metabolism  
 disorders of, 413–414  
 mechanism of action, 4–5  
 serotonin regulation, 15  
 stress response, 3, 5, 9, 10, 18
- Glutamate systems, 16–17
- Glycoprotein, ?1-acid, 35
- Gonadal hormone disorders, 415–416
- Gonadal steroids, 5–7, 18
- Growth hormone, 404, 405, 414–415
- H**
- Hallucinations, 586, 587–588
- Heart transplantation, 425
- Helicobacter pylori, 442
- Hepatitis, viral, 446
- Herbal medicine, 346–348
- Histrionic personality disorder, 323–324, 325
- Homeopathic medicine, 348–349
- Hormonal system  
 adrenal hyperplasia, 501  
 in anxiety, 4, 12–18, 197  
 cardiac disease and, 426–427  
 depression and, 4, 148–149  
 gonadal steroid mechanisms, 5–7  
 in lactation, 14  
 in panic disorder  
 pathophysiology, 203  
 premenstrual symptom  
 intervention, 59–62  
 sexual behavior and, 263, 264  
 in sleep regulation, 276–277  
 stress response, 3–4, 5, 8–11, 13–18  
 treatment of postpartum mental disorders, 101  
*see also* Contraception, hormonal; specific hormone
- Hot flushes, 135–136, 278
- Human papillomavirus, 378, 455
- 5-Hydroxytryptophan, 15–16
- Hyperglycemia, 405
- Hypnotherapy, 350–351
- Hypnotic drugs, 283–284
- Hypochondriasis  
 comorbidity, 313, 315  
 course, 312  
 diagnostic criteria, 307  
 epidemiology, 311  
 treatment response, 317–318
- Hypoglycemia, 406
- Hypothalamic–pituitary–adrenal axis  
 in anxiety, 7–8  
 in depression, 7–8, 149, 412–413  
 function, 412  
 glucocorticoid disorders, 413–414  
 gonadal hormone disorders, 415–416  
 growth hormone disorders, 413–414  
 in lactation, 14  
 parathyroid hormone disorders, 416  
 in posttraumatic stress disorder, 213  
 during pregnancy, 72–73  
 prolactin disorders, 416  
 sex differences, 8–9, 10  
 stress response, 3, 4–5, 8–11
- Hypothalamic–pituitary–thyroid axis, 410, 411
- I**
- Ileostomy, 443–444
- Immigrant women, 574–577
- Infertility  
 anorexia nervosa and, 253  
 cancer treatment-related, 377  
 inflammatory bowel disease and, 444  
 psychological reactions to, 360  
 schizophrenia and, 189–190
- Inflammatory bowel disease, 442–444
- Intrauterine device, 120
- Irritable bowel syndrome, 444–446
- K**
- Kidneys  
 eating disorder complications, 251  
 pharmacokinetic role, 36–37
- L**
- Lesbian women  
 clinical conceptualization, 555–556  
 development, 557–559  
 family-of-origin issues, 560–561  
 incidence, 556–557  
 mental health treatment, 561, 562–563  
 origins, 557  
 as parents, 520, 560  
 relationship characteristics, 518, 559  
 social acceptance, 556  
 status of psychology research, 555, 563  
 therapeutic relationship, 561–562
- Levonorgestrol, 119, 120
- Life expectancy, 584
- Light exposure therapy, 58, 286
- Liposuction, 488
- Lithium  
 for bipolar disorder, 167–168  
 discontinuation effects, 73  
 ethnic differences in metabolism, 579  
 fetal exposure, 77–78, 81–82, 171–172  
 use during pregnancy, 81, 82
- Liver  
 alcohol effects, 230  
 drug biotransformation in, 32  
 drug–drug interactions, 446–447  
 fatty liver of pregnancy, 446  
 hormonal contraceptive effects, 125  
 viral hepatitis, 446
- Locus coeruleus, 6, 7–8, 445
- Lung cancer  
 epidemiology, 380–381  
 family functioning and, 382  
 long-term survivors, 383–384  
 prognosis, 381  
 psychological response, 381–383  
 risk factors, 381  
 smoking and, 383  
 treatment, 381
- Lupus erythematosus, systemic  
 complications, 396  
 diagnosis, 395  
 drug-induced, 396  
 epidemiology, 395–396  
 reproductive function and, 396  
 treatment, 396–397
- Luteinizing hormone, 404, 405
- M**
- Magnesium, premenstrual symptoms and, 56–58
- Mammography, 370
- Marriage  
 depression and, 151  
 distribution of labor in, 516, 517, 518  
 divorce, 521–523  
 dual-career/dual-work couples, 530–531  
 lesbian and gay relationships, 518, 520, 559  
 parenting practices in, 520  
 satisfaction, 516–517, 518, 520  
 socialization pressure for, 517–518  
 sources of stress, 516  
 substance abuse patterns, 224  
 trends, 515–516, 518  
 working women and, 530
- Mastectomy, 371, 372–373
- Melatonin, 279, 284–285
- Menopause  
 bipolar disorder and, 175  
 cancer treatment-related, 377  
 definition, 134  
 depression and, 133–137, 137  
 estrogen replacement therapy in, 137–139  
 menstrual migraine and, 470  
 physiology, 137–133  
 psychosocial context, 136–137  
 sexuality in, 263–264  
 sleep architecture during, 278  
 surgical, 133, 135  
 thyroid function in, 411–412  
 vasomotor symptoms, 136  
 women's expectations, 137  
*see also* Perimenopausal woman
- Menstruation  
 alcohol effects and, 229, 230  
 anxiety and, 12–13, 197, 200

- Menstruation (*continued*)  
 assessment of psychiatric symptoms, 48–49, 54–56  
 bipolar disorder and, 168–169  
 body temperature changes, 279  
 Depo Provera effects, 118  
 depression and, 149, 154–155  
 hormonal contraception effects, 117  
 migraine related to, 469–470  
 obsessive–compulsive disorder and, 210  
 panic disorder and, 203  
 pharmacokinetic changes in, 35, 603, 607  
 premenstrual magnification/exacerbation, 53  
 psychotic symptoms in, 53–54  
 sleep patterns and, 277, 283, 288  
 sociocultural context, 49  
 stress response, 10  
 thyroid function in, 411  
*see also* Premenstrual dysphoric disorder; Premenstrual syndrome
- Migraine  
 classification, 468  
 clinical features, 468  
 epidemiology, 467  
 evaluation, 470  
 health-seeking behavior, 467–468  
 menstrual, 469–470  
 pathogenesis, 468–469  
 social costs, 467  
 treatment, 470–471
- Miscarriage, 361
- Monoamine oxidase inhibitors, 40  
 effects on sleep, 284  
 fetal exposure, 75  
 panic disorder management, 202, 204  
 personality disorder treatment, 335  
 posttraumatic stress disorder treatment, 212  
 social anxiety disorder treatment, 207
- Morning-after pills, 120
- Multiple sclerosis  
 clinical features, 472–473  
 cognitive dysfunction in, 473  
 diagnosis, 474  
 emotional disorders related to, 473  
 epidemiology, 472  
 etiology, 472  
 pathogenesis, 472  
 treatment, 474–475
- Myocardial infarction, 424, 426
- N**
- Narcissistic personality disorder, 323, 324, 325
- National Institutes of Health, 597, 598, 599, 613–614
- Nausea, 441–442
- Neurobiology  
 effects of maternal mental illness on offspring, 96  
 estrogen action, 135, 202–203, 587  
 of gender socialization, 509–510  
 of generalized anxiety disorder, 199–200  
 of irritable bowel syndrome, 445  
 of panic disorder, 202  
 pharmacodynamic effects, 603–604  
 progesterone action, 202–203  
 of sleep, 275–276  
 of social anxiety disorder, 206–207  
 stress response  
 basic mechanisms, 3–8  
 gonadosteroid effects, 8–17  
 Neuroleptic drugs, 37–38, 76–77, 335  
 Neurosteroid hormones, 6–7  
 Night-eating syndrome, 247, 248  
 N-methyl-D-aspartate, 16, 17  
 Norplant, 119, 121, 123
- O**
- Obesity, 440–441
- Obsessive–compulsive disorder, 83, 95
- Obsessive–compulsive disorder, 324, 325  
 among elderly, 589  
 comorbidity, 208–209, 210  
 course, 208, 616  
 epidemiology, 195, 208  
 gender differences, 209–210  
 reproductive cycle correlations, 210–211  
 somatoform disorder  
 comorbidity, 313  
 treatment, 209, 210
- Older women, 537  
 anxiety disorders among, 589  
 depression, 585–586  
 life expectancy, 584  
 mental health risks, 589–590  
 mental health treatment, 624–625  
 personality disorders among, 589  
 psychosis among, 587–588  
 sexual functioning, 263–264  
 substance abuse among, 226, 588–589
- Oophorectomy, 133
- Osteoporosis, 116, 251
- Outcomes research, 618–619
- Ovarian cancer, 379–380  
 hormonal contraception and, 117  
 prophylactic oophorectomy, 133  
 risk, 117
- Oxytocin, 404
- P**
- Pain disorder  
 chronic pelvic pain, 363–366  
 diagnostic criteria, 307  
 epidemiology, 311  
 treatment response, 319–320
- Panic disorder  
 among elderly, 589  
 comorbidity, 201–202, 333  
 epidemiology, 195, 200  
 gender differences, 201–202  
 genetics, 202  
 help-seeking behaviors, 201  
 hormonal contraception and, 123–124  
 neurobiology, 202  
 outcomes, 200–201, 202  
 pregnancy and, 82–83, 95  
 reproductive cycle correlations, 202–204  
 somatoform disorder  
 comorbidity, 313, 314  
 treatment, 204
- Paranoid personality disorder, 323
- Parathyroid hormone disorders, 416
- Parenting  
 child-bearing trends, 519  
 divorce effects, 522–523  
 lesbian mothers, 520, 560  
 marital satisfaction and, 520  
 role stress in, 518, 519–520  
 single-parent households, 520–521  
 sociocultural expectations, 518–519  
 as source of stress, 519  
 by working mothers, 530–531
- Passive–aggressive personality, 324
- Peptic ulcer disease, 442
- Perimenopausal woman  
 anxiety sensitivity in, 197  
 contraception use, 121–122  
 depression risk, 149  
 hot flushes, 121–122  
 sleep patterns, 278
- Periodic limb movement syndrome, 281
- Personality disorders  
 among elderly, 589  
 classification, 323–324, 325–329, 336–338  
 comorbidity, 332–334  
 cosmetic surgery and, 488–489  
 definition, 323  
 epidemiology, 324–326  
 etiology, 329–332  
 somatoform disorder  
 comorbidity, 314–315  
 treatment, 334–336
- Pharmaceutical research  
 behavioral pharmacology, 604–605  
 compliance behaviors, 622  
 efficacy of study treatment, 601–602  
 inadequacies in, 597–598, 622–623  
 life cycle issues, 606  
 menstrual cycle effects, 607  
 opportunities for improving, 608–609  
 patient recruitment, 598–599  
 pharmacodynamic effects, 603–604  
 pharmacokinetics, 602–603  
 pregnancy factors, 623–624  
 safety and tolerability, 605–606  
 sex/gender issues, 597–598, 607–608, 613–614  
 sleep effects, 605  
 study entry, 600–601  
 utilization patterns, 621–622
- Pharmacokinetics  
 absorption, 32, 34  
 antidepressant medications, 39–40, 41

- antipsychotic agents, 37–38, 41  
 benzodiazepines, 38–39  
 bioavailability, 34  
 biotransformation in liver, 32  
 clinical significance, 31–32, 34  
 conjugation, 36–37  
 cytochrome P450 enzyme in, 32–33, 35–36  
 drug distribution, 32, 34–35  
 elimination, 32, 36–37  
 ethnic differences in, 579  
 metabolism, 32, 35–37  
 in schizophrenia, 188–189  
 sex differences in, 31, 34–41, 155  
 sex-specific research, 602–603
- Pharmacotherapy  
 adverse effects on sexual functioning, 267  
 Alzheimer's disease, 476–477  
 body dysmorphic disorder, 300–301, 302–303  
 breastfeeding and, 172–174  
 chronic fatigue syndrome, 392–393  
 compliance, 622  
 depression, 155–157  
 eating disorders, 255–257  
 ethnicity considerations, 579–580  
 fetal risk, 169–172  
 fibromyalgia, 395  
 gastroesophageal reflux disease, 440  
 generalized anxiety disorder, 200  
 inflammatory bowel disease, 443  
 insomnia treatment, 283–285  
 irritable bowel syndrome, 446  
 liver complications, 446–447  
 lupus erythematosus induced by, 396  
 migraine, 470–471  
 multiple sclerosis, 474–475  
 myocardial infarction, 424  
 nausea in pregnancy, 441–442  
 obesity, 441  
 obsessive–compulsive disorder, 209, 210  
 pain disorder with psychological features, 319–320  
 panic disorder, 204  
 personality disorder treatment, 334–336  
 pharmacokinetics in, significance of, 31–32, 34  
 postpartum mental disorders, 101  
 posttraumatic stress disorder, 212  
 during pregnancy, 83–84  
 discontinuation effects, 73  
 fetal exposure risks, 70–79  
 treatment guidelines, 79–84  
 premenstrual disorders, 58–62  
 psychiatric disorders in AIDS/HIV, 460–461  
 rheumatoid arthritis, 398  
 schizophrenia, 188–189  
 for sexual dysfunction, 266–267  
 social anxiety disorder, 207  
 somatoform disorder and, 312–313  
 trauma exposure treatment, 550–551
- utilization patterns, 621–622  
*see also* Drug interactions;  
 Pharmaceutical research;  
 Pharmacokinetics
- Pheochromocytoma, 414
- Phobias  
 among older women, 589  
 comorbid disorders, 205  
 epidemiology, 204–205  
 gender differences in, 205
- Phototherapy, 158
- Pituitary function, 404–405
- Polycystic ovaries, 415–416
- Postpartum period  
 anxiety sensitivity in, 197  
 bipolar disorder in, 172  
 classification of mental disorders in, 92  
 clinical conceptualization, 91, 92  
 mental health resources, 96–97  
 obsessive–compulsive disorder in, 95, 210–211  
 panic disorder in, 95, 204  
 postpartum blues, 92–93  
 postpartum depression, 93–94, 103, 149, 620, 624  
 postpartum psychosis, 94  
 research opportunities, 103  
 risk of mental disorders in, 91, 97  
 sleep architecture during, 277–278  
 thyroid function in, 411  
 treatment of mental disorders in, 96–101
- Posttraumatic stress disorder  
 comorbidity, 201, 211–212, 546  
 course, 545  
 epidemiology, 195, 211, 544, 546  
 outcomes, 547–548  
 reproductive cycle correlations, 213  
 risk factors, 212–213, 545  
 schizophrenia and, 186–187, 190  
 sex differences, 212–213, 545, 621  
 somatization response, 547  
 treatment, 212, 548–551
- Pregnancy  
 acute fatty liver of, 446  
 addiction counseling/treatment, 234, 235  
 adolescent, 120–121  
 after sexual assault, 548  
 anxiety and, 13–14, 82–83, 197–198  
 bipolar disorder in, 81–82, 169–172  
 body dysmorphic disorder treatment during, 303  
 cardiac transplantation and, 425  
 depression in, 80–81  
 eating disorder and, 253–254  
 ectopic, 117  
 ethical issues in treatment, 623–624  
 fibromyalgia symptoms in, 394  
 gastroesophageal reflux disease in, 439  
 HIV transmission, 455  
 hormonal changes in, 203–204
- hypothalamic–pituitary–adrenal axis changes in, 411  
 inflammatory bowel disease and, 444  
 mental health screening during, 620  
 miscarriage reactions, 361  
 nausea during, 441–442  
 obsessive–compulsive disorder in, 210–211  
 panic disorder in, 203–204  
 pharmacotherapy during, 623–624  
 posttraumatic stress disorder and, 213  
 prevention of postpartum mental disorder, 97, 101–102  
 psychiatric illness during pharmacotherapy risks, 70–79, 83–84  
 risk of, 70  
 treatment guidelines, 79–84  
 sexuality during, 263  
 sleep patterns during, 277–278  
 stress effects, 13–14, 72–73  
 substance abuse and, 230–232  
 unintended, 362–363
- Premenstrual dysphoric disorder, 149  
 assessment and diagnosis, 48–49, 54–56  
 bipolar disorder and, 169  
 clinical conceptualization, 51–52, 62  
 depression and, 52  
 differential diagnosis, 53, 56  
 etiology, 49  
 management, 49, 56–62  
 pharmacotherapy and, 607  
 risk factors, 50  
 sleep patterns in, 277
- Premenstrual syndrome  
 assessment and diagnosis, 48–49, 54–56  
 clinical conceptualization, 50, 51  
 differential diagnosis, 53  
 epidemiology, 51  
 etiology, 49  
 management, 49, 51, 56–62  
 risk factors, 50  
*see also* Premenstrual dysphoric disorder
- Progesterone  
 anxiety and, 12–13, 18  
 in anxiety disorder pathogenesis, 197  
 drug interactions, 284  
 effects on sleep, 276–277  
 glucocorticoid interaction, 9, 10  
 in postpartum mood disturbances, 93, 101, 102  
 for premenstrual disorders, 61  
 in serotonergic regulation, 16  
 in stress response, 10
- Progestin  
 androgenicity, 115–116  
 in Depo Provera, 118–119  
 in Norplant, 119  
 in oral contraceptive pill, 114, 119–120, 122–123
- Prolactin, 404, 416

- Prolactin levels, 188–189  
 in depression, 410–411  
 disorders of, 416  
 psychological manifestations, 416  
 regulation, 416  
 thyroid function in, 410  
 Protease inhibitors, 460  
 Psychopathology  
 in AIDS/HIV, 456, 457–458, 461  
 assessment and diagnosis, 617–618  
 cosmetic surgery and, 482–484, 486–489  
 developmental epidemiology, 615  
 diabetes complications, 407–410  
 effects of maternal mental illness on offspring, 95–96  
 hormonal contraception use and, 122–124  
 inflammatory bowel disease and, 443, 444  
 menstrual psychosis, 53–54  
 mental health screening, 619–620  
 obesity and, 440  
 pharmacotherapy. *see* Pharmacotherapy  
 in postpartum period, 91  
 prevention, 101–102  
 treatment, 96–101  
 in pregnancy  
 risk of, 70  
 treatment, 72–73, 79, 83–84  
 premenstrual magnification/exacerbation, 53  
 principal sources of disability, 615  
 psychotic disorders among elderly, 587–588  
 rheumatoid arthritis  
 complications  
 risk of premenstrual disorder, 50  
 somatoform disorder  
 comorbidity, 313–315  
*see also* specific disorder  
 Psychosis  
 menstrual, 53–54  
 postpartum, 94  
 Psychosocial functioning  
 AIDS/HIV complications, 459  
 body dysmorphic disorder  
 manifestations, 297–298  
 breast cancer response, 371–372, 375  
 cancer survivors, 383–384  
 cardiac disease risk factors, 428–430  
 coping style, 150  
 cultural context, 569–570  
 diabetes complications, 405–406  
 immigrant experience, 574–577  
 lung cancer response, 381–383  
 in menopause, 136–137  
 mental health status of women, 614–615  
 multiple sclerosis complications, 473  
 reconstructive surgery effects, 489–490  
 role of cultural identity, 572–574  
 schizophrenia outcomes, 186–188  
 sexual dysfunction secondary to  
 problems of, 265–266  
 sleep behavior and, 282–283  
 socialization experience,  
 depression and, 150  
 substance abuse-associated, 227–228  
 trauma exposure outcomes, 547–548  
 Psychotherapy  
 with AIDS/HIV patient, 462–463  
 Alzheimer's disease management, 477  
 body dysmorphic disorder  
 treatment, 301–304  
 for breast cancer patient, 375  
 for bulimia nervosa, 255–256  
 for conversion disorder, 316–317  
 cultural competence in, 568, 569–570, 577–579  
 depression, 157  
 fibromyalgia treatment, 395  
 for hypochondriasis, 316–317  
 insomnia treatment, 284  
 with lesbians, 561–563  
 lung cancer intervention, 382–383  
 for multiple sclerosis, 475  
 for nausea in pregnancy, 442  
 for pain disorder with  
 psychological features, 319  
 personality disorder treatment, 334, 336  
 for postpartum mental disorders, 97–101, 624  
 for premenstrual disorders, 58  
 sex differences, 157  
 for sexual dysfunction, 269  
 with sexual harassment targets, 535  
 for somatization disorder, 316  
 trauma exposure treatment, 548–551  
 Puberty, depression risk in, 149  
 Public health  
 diagnostic issues in women's  
 mental health, 617–618  
 ethical issues in treatment, 622–624  
 implications of gender differences  
 in mental health, 617, 620–622, 624–625  
 mental health status of women,  
 614–615  
 opportunities for improving,  
 624–625  
 outcomes research methodology,  
 618–619  
 screening, 619–620  
 utilization patterns, 621  
**R**  
 Race and ethnicity  
 AIDS/HIV infection and, 453–454, 459, 463  
 clinical significance, 568  
 cultural identity, 572–574  
 culturally competent practice,  
 568, 569–570, 577–579  
 diversity within and among  
 minority groups, 568–569  
 help-seeking behaviors, 571–572  
 immigrant women, 574–577  
 implications for  
 pharmacotherapy, 579–580  
 lesbian and gay relationships,  
 559  
 lupus risk, 395–396  
 marriage patterns, 516  
 mental health implications of  
 culture, 569–570  
 obstacles to utilization, 571, 572  
 parenting practices, 519, 520–521  
 sexual dysfunction, 265  
 social stressors for minorities,  
 570–571  
 substance abuse patterns, 224  
 suicide risk, 585–586  
 Radiation therapy, 373  
 Reconstructive surgery, 489–492  
 Relaxation training, 471  
 Rheumatoid arthritis, 397–398  
 Rheumatological disease  
 chronic fatigue syndrome, 390–393  
 clinical conceptualization, 398–399  
 fibromyalgia, 393–395  
 lupus erythematosus, systemic,  
 395–397  
 psychological comorbidity, 390, 399  
 rheumatoid arthritis, 397–398  
 risk, 390  
**S**  
 Salpingitis, 117  
 Schizoid/schizotypal personality  
 disorder, 323, 325, 328  
 Schizophrenia, 328  
 clinical features, 182, 183–184  
 cosmetic surgery and, 487  
 course, 184–185, 616  
 diabetes mellitus and, 407–408  
 epidemiology, 184–185, 615  
 estrogen effects, 37  
 future research, 190–191  
 gender differences, 182–191, 616  
 late-onset, 588  
 neurocognitive functioning in,  
 185–186  
 psychosocial outcomes, 186–188  
 sexuality and fertility, 189–190  
 somatoform disorder  
 comorbidity, 313  
 substance abuse and, 187–188  
 treatment, 188–189  
 Seasonal affective disorder, 154  
 Sedatives, 283–284  
 Seizures, 16–17, 78–79  
 Selective serotonin reuptake  
 inhibitors  
 AIDS/HIV and, 460  
 body dysmorphic disorder  
 treatment, 300–301, 302–303  
 breastfeeding and, 103  
 fetal exposure, 74, 75  
 obsessive-compulsive disorder  
 treatment, 209  
 panic disorder management, 204  
 personality disorder treatment,  
 336

- posttraumatic stress disorder  
   treatment, 212  
 for premenstrual disorders, 58–59  
 sex differences in  
   pharmacokinetics, 40  
 social anxiety disorder treatment, 207  
 Serotonergic system  
   estrogen effects, 125, 135  
   in menopause, 135  
   in premenstrual symptoms, 49  
   sex differences, 15–16  
   stress response, 15  
 Sexual harassment  
   outcomes, 534–535  
   psychological interventions with  
     targets of, 535  
   in workplace, 533, 536  
   workplace policies, 536  
 Sexuality/sexual functioning  
   AIDS/HIV risk, 453, 457–458  
   alcohol use and, 225, 228–229  
   assessment, 268–269  
   biology, 264  
   breast cancer patient, 375  
   cardiac disease and, 426  
   diabetes complications, 406–407  
   gynecological cancer and, 377  
   hormonal contraceptive effects,  
     124–125  
   life course, 263–264  
   medication side effects, 267,  
     269–270  
   medications to enhance, 266–267  
   orgasm, 264  
   primary sexual disorders, 265  
   in schizophrenia, 189–190  
   secondary dysfunctions, 265–268  
   substance abuse and, 231, 266  
   treatment of dysfunction, 269–  
     270  
   *see also* Lesbian women  
 Sleep, 135–136  
   age-related changes, 275  
   apneas, 280  
   breathing in, 275–276, 279–280  
   circadian patterns, 278–279  
   cognitive factors, 282–283  
   comorbid disorders in insomnia,  
     287–288  
   environmental factors, 282  
   estrogen replacement therapy  
     effects, 138  
   hormonal regulation, 276–277  
   insomnia diagnosis, 283  
   insomnia treatment, 283–286  
   limb movement disorders, 281  
   during menopause, 278  
   menstrual cycle effects, 277  
   parasomnias, 286–287  
   pharmaceutical research, 605  
   physiology, 275–278  
   during pregnancy, 277–278  
   substance use and, 281–282  
   treatment for problems of, 274  
 Smoking, 225, 233  
   cardiovascular disease and, 423  
   depression in diabetes mellitus  
     and, 408  
   effects on sleep, 282  
   epidemiology, 223  
   lung cancer and, 380–381, 383  
   physiological effects, 230–231  
   during pregnancy, 231  
   trends, 383  
 Snoring, 280  
 Social anxiety disorder  
   clinical features, 205–206  
   comorbid disorders, 206  
   epidemiology, 195, 205  
   gender factors in, 207–208  
   genetics, 207  
   neurobiology, 206–207  
   risk factors, 206  
   treatment, 207  
 Social learning theory, 505–506,  
   523  
 Somatoform disorders, 320, 332  
   comorbidity, 313–315  
   course, 312–313  
   definition, 307  
   diagnostic categories, 307  
   diagnostic criteria, 307  
   epidemiology, 307–311  
   gender differences, 309–310,  
     311–312  
   presentation, 311–312  
   trauma response, 547  
   treatment response, 315–320  
 Stimulants, 282, 460–461  
 Stress  
   anxiety and, 3–4, 18  
   cardiac disease risk factors, 428–  
     429  
   depression and, 3–4, 18, 150–  
     151, 154  
   effects on neural structure, 11  
   effects on sleep, 283  
   elder care, 537  
   in gender socialization, 523  
   hypothalamic–pituitary–adrenal  
     axis regulation, 4–5, 8–11  
   immigrant experience, 575–576  
   lactation effects, 14  
   in marriage, 516  
   measurement, 9–10  
   migraine and, 470  
   neurophysiological systems in, 3–  
     4  
   of parenting, 519–520  
   pregnancy effects, 13–14, 72–73  
   premenstrual disorder and, 50  
   prenatal, 11  
   role conflict/strain for working  
     women, 531–532  
   serotonin action in, 15  
   sex differences in, 5, 6, 11, 620–  
     621  
   workplace, 529  
 Stress inoculation training, 550  
 Substance abuse  
   addiction treatment, 234–236  
   AIDS/HIV and, 453, 457, 459  
   among elderly, 588–589  
   associated factors, 227–229,  
     232–233  
   comorbidity, 201, 202, 223,  
     232–233  
   course, 232  
   depression and, 153  
   effects on sleep, 281, 282  
   epidemiology, 222, 223  
   future research directions, 237  
   gender differences, 222–226,  
     227–231, 232–237  
   pain disorder pharmacotherapy  
     and, 320  
   during pregnancy, 230–232  
   prevention, 236–237  
   prognosis, 234  
   schizophrenia and, 187–188  
   sexual behavior and, 231, 266  
   *see also* Alcohol use and abuse  
 Suicide  
   among elderly, 585–586  
   among lesbian adolescents, 558  
   body dysmorphic disorder and,  
     298  
   diabetes mellitus and, 408  
   epidemiology, 134  
   gender differences, 152–153,  
     166–167  
   substance abuse and, 228  
 Surgical intervention  
   body dysmorphic disorder  
     treatment, 300  
   breast cancer treatment, 372–373  
   for inflammatory bowel disease,  
     443–444  
   for premenstrual disorders, 62  
   prophylactic oophorectomy, 133  
   *see also* Cosmetic surgery;  
     Reconstructive surgery  
**T**  
 Tardive dyskinesia, 38  
 Taste perception, 438  
 Temperature regulation, 135–136,  
   279  
 Testosterone, 264  
   brain metabolism, 6  
   in congenital adrenal  
     hyperplasia, 501  
   disorders of, 415–416  
   in gender socialization process,  
     509–510  
 Thrombolytic medications, 424  
 Thyroid function, 410  
   in bipolar disorder, 167  
   in depression, 153, 410, 412  
   in menopause, 411–412  
   postpartum, 411  
   in premenstrual period, 411  
   psychological manifestations of,  
     410  
   regulation, 410  
 Thyroid-stimulating hormone, 404  
 Trauma exposure  
   anxiety disorder risk, 197  
   clinical conceptualization, 542  
   depression risk, 151  
   dissociation response, 546–547  
   effects, 544–548  
   immigrant experience, 575  
   research needs, 551  
   scope of problem, 542–544  
   sex differences, 212  
   substance abuse and, 232–233  
   treatment, 548–551  
   *see also* Abuse, physical/sexual;  
     Posttraumatic stress disorder;  
     Violence exposure  
 Tricyclic antidepressants  
   for borderline personality  
     disorder, 335  
   drug interactions, 127  
   fetal exposure, 73–74, 75, 80–81

- Tricyclic antidepressants (*continued*)  
  insomnia treatment, 284  
  obsessive-compulsive disorder  
    treatment, 209  
  panic disorder management, 204  
  posttraumatic stress disorder  
    treatment, 212  
  sex differences in response to,  
    155–156, 157  
  use during pregnancy, 82, 83  
Type A behavior, 428
- U**  
Ulcerative colitis, 442–444  
Uterine cancer, 378–379
- V**  
Violence exposure  
  epidemiology, 544  
  outcomes, 548  
  research needs, 551  
  scope of problem, 542–543
- see also* Abuse, physical/sexual;  
  Trauma exposure  
Vitamin B<sub>6</sub>, 56  
Vulvar cancer, 380
- W**  
Work/working. *see* Employment
- Y**  
Yoga, 351–352